391 related articles for article (PubMed ID: 28325253)
1. Efficacy and safety of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Yoodee J; Permsuwan U; Nimworapan M
Crit Rev Oncol Hematol; 2017 Apr; 112():113-125. PubMed ID: 28325253
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review.
Chow R; Chiu L; Navari R; Passik S; Chiu N; Popovic M; Lam H; Pasetka M; Chow E; DeAngelis C
Support Care Cancer; 2016 Feb; 24(2):1001-1008. PubMed ID: 26530228
[TBL] [Abstract][Full Text] [Related]
3. A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting.
Wang XF; Feng Y; Chen Y; Gao BL; Han BH
Sci Rep; 2014 Apr; 4():4813. PubMed ID: 24770591
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis.
Chiu L; Chow R; Popovic M; Navari RM; Shumway NM; Chiu N; Lam H; Milakovic M; Pasetka M; Vuong S; Chow E; DeAngelis C
Support Care Cancer; 2016 May; 24(5):2381-2392. PubMed ID: 26768437
[TBL] [Abstract][Full Text] [Related]
5. Secondary and cumulative meta-analysis of olanzapine for antiemetic prophylaxis for chemotherapy-induced nausea and vomiting: do we still need to study its effectiveness?
Chiu L; Chow R; DeAngelis C; Lock M; Simone CB
Ann Palliat Med; 2021 Mar; 10(3):2540-2547. PubMed ID: 33440973
[TBL] [Abstract][Full Text] [Related]
6. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review.
Hocking CM; Kichenadasse G
Support Care Cancer; 2014 Apr; 22(4):1143-51. PubMed ID: 24522741
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting (CINV): a retrospective study.
Chiu L; Chiu N; Chow R; Zhang L; Pasetka M; Stinson J; Lechner B; Pulenzas N; Verma S; Chow E; DeAngelis C
Ann Palliat Med; 2016 Jul; 5(3):172-8. PubMed ID: 27199269
[TBL] [Abstract][Full Text] [Related]
8. Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature.
Chow R; Herrstedt J; Aapro M; Chiu L; Lam H; Prsic E; Lock M; DeAngelis C; Navari RM
Support Care Cancer; 2021 Jul; 29(7):3439-3459. PubMed ID: 33442782
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting: a meta-analysis.
Yang T; Liu Q; Lu M; Ma L; Zhou Y; Cui Y
Br J Clin Pharmacol; 2017 Jul; 83(7):1369-1379. PubMed ID: 28112422
[TBL] [Abstract][Full Text] [Related]
10. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of olanzapine, neurokinin-1 receptor antagonists, and thalidomide in combination with palonosetron plus dexamethasone in preventing highly emetogenic chemotherapy-induced nausea and vomiting: a Bayesian network meta-analysis.
Alhifany AA; McBride A; Almutairi AR; Cheema E; Shahbar A; Alatawi Y; Alharbi AS; Babiker H; MacDonald K; Aapro M; Abraham I
Support Care Cancer; 2020 Mar; 28(3):1031-1039. PubMed ID: 31823054
[TBL] [Abstract][Full Text] [Related]
12. Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Bosnjak SM; Dimitrijevic J; Djordjevic F
Curr Opin Support Palliat Care; 2016 Jun; 10(2):180-8. PubMed ID: 27028050
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Olanzapine for the Prevention of Chemotherapy-induced Nausea and Vomiting in Children: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Meena JP; Gupta AK; Jat KR; Anandani G; Sasidharan A; Tanwar P
J Pediatr Hematol Oncol; 2023 Oct; 45(7):361-369. PubMed ID: 37539996
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: A systematic review and network meta-analysis.
Filetti M; Lombardi P; Giusti R; Falcone R; Scotte F; Giannarelli D; Carcagnì A; Altamura V; Scambia G; Daniele G
Cancer Treat Rev; 2023 Apr; 115():102512. PubMed ID: 36774658
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Chow R; Tsao M; Chiu L; Popovic M; Milakovic M; Lam H; DeAngelis C
Ann Palliat Med; 2018 Apr; 7(2):221-233. PubMed ID: 29764184
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial.
Abe M; Hirashima Y; Kasamatsu Y; Kado N; Komeda S; Kuji S; Tanaka A; Takahashi N; Takekuma M; Hihara H; Ichikawa Y; Itonaga Y; Hirakawa T; Nasu K; Miyagi K; Murakami J; Ito K
Support Care Cancer; 2016 Feb; 24(2):675-682. PubMed ID: 26130365
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.
Zhou JG; Huang L; Jin SH; Xu C; Frey B; Ma H; Gaipl US
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079622
[TBL] [Abstract][Full Text] [Related]
18. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.
Liu J; Tan L; Zhang H; Li H; Liu X; Yan Z; Chen J; Yang H; Zhang D
Eur J Cancer Care (Engl); 2015 May; 24(3):436-43. PubMed ID: 25404537
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier Oncology Group study.
Navari RM; Einhorn LH; Passik SD; Loehrer PJ; Johnson C; Mayer ML; McClean J; Vinson J; Pletcher W
Support Care Cancer; 2005 Jul; 13(7):529-34. PubMed ID: 15700131
[TBL] [Abstract][Full Text] [Related]
20. Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy.
Slimano F; Netzer F; Borget I; Lemare F; Besse B
Int J Clin Pharm; 2018 Oct; 40(5):1265-1271. PubMed ID: 29744791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
